P071

Targeting Twist1-Hoxa9 to sensitize prostate cancer to PARP inhibition

By: Malek R.1, Gajula R.2, Williams R.2, Nghiem B.3, Simons B.4, Wang H.2, Taparra K.2, Barbhuiya M.2, Deweese T.2, Pienta K.4, Hurley P.4, Morrissey C.3, Tran P.2
Institutes: 1Johns Hopkins University School of Medicine, Radiation Oncology and Molecular Radiation Sciences, Baltimore, United States of America, 2Johns Hopkins University School of Medicine, Dept. of Radiation Oncology and Molecular Radiation Sciences, Baltimore, United States of America, 3University of Washington, Dept. of Pathology, Seattle, United States of America, 4Johns Hopkins University School of Medicine, Dept. of Urology, Baltimore, United States of America

Introduction & Objectives

Personalized molecular strategies to identify prostate cancer (CaP) patients that are more likely to respond to specific treatment would result in better outcomes and less overtreatment. A recent example is the sensitivity of metastatic prostate cancers to PARP inhibition in only those patients that have defects in DNA damage response (DDR). Recently, acute myelogenous leukemias positive for Mixed Lineage Leukemia (MLL) fusion proteins have been shown to overexpress HOXA9 which in turn leads to increased expression of DDR genes thereby facilitating resistance to PARP inhibitor therapy. Inhibiting HOXA9 resulted in restoring sensitivity of MLL positive AML cells to PARP inhibitors. TWIST1 is a master transcriptional regulator of the EMT that plays key roles during development and can promote cancer metastasis. We have demonstrated that TWIST1 activates transcription of HOXA9 which contributes to the induction of a TWIST1-dependent metastatic phenotype in prostate cancer. Further, we have found that TWIST1 forms a complex with the MLL/COMPASS methyltransferase complex and this complex activates HOXA9 expression by H3K4me3 chromatin modification of the HOXA9 promoter region. The goal of this project is 1) to investigate whether HOXA9 expression occurs along with TWIST1 in vivo and 2) determine whether HOXA9 can lead to expression of DDR genes in prostate cancer and thus, PARP inhibitor resistance and 3) determine whether inhibiting HOXA9 will dampen TWIST1-mediated pro-metastatic responses and sensitize these cells to PARP inhibition.

Results

We found that TWIST1 is expressed along with HOXA9 in the developing prostate with peak expression occurring at ~ E17.5. TWIST1 and HOXA9 are re-expressed in at least one model of mouse prostate cancer. Importantly, we found co-expression of TWIST1 and HOXA9 in a subset of primary CaP tumors in patient samples and their expression was significantly enriched in metastatic samples. Furthermore, alterations in TWIST1 and HOXA9 were associated with decreased survival in patient data from cBIO. In support of our previous data, we show that inhibition of HOXA9 using a peptide inhibitor decreased the pro-metastatic behavior of TWIST1 over-expressing Myc-CaP and PC3 cells in vitro and in vivo.

Conclusions

TWIST1 plays key roles during development and is a master transcriptional regulator of epithelial plasticity programs that can promote cancer metastasis. We demonstrate that HOXA9 may be a target of TWIST1 during development and this phenomenon is reactivated in CaP progression. We show that HOXA9 inhibition can dampen TWIST1-dependent pro-metastatic behavior suggesting that HOXA9 is a potential target for combination therapy in metastatic CaP.

  • Event: 9th European Multidisciplinary congress on Urological Cancers
  • Type: Abstract
  • Date: 16-11-2017
  • Views: 181
  • Nr: P071